AstraZeneca’s asthma drug Fasenra looks promising for a set of rare chronic immune diseases

AstraZeneca’s asthma drug Fasenra looks promising for a set of rare chronic immune diseases

Source: 
Endpoints
snippet: 

Just 16 months after the FDA approved AstraZeneca’s Fasenra for a severe form of asthma, investigators at the NIH have found that the drug appears to hold great promise for treating rare chronic immune disorders called hypereosinophilic syndromes, or HES.